Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Experts call for integrated, evidence-based approaches to tackle rising dengue, malaria, and chikungunya burden in Indian cities
The approval was driven by data from the Phase III TULIP-SC trial
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
India leads the shift as wellness tourism integrates healthcare, hospitality, and lifestyle
Subscribe To Our Newsletter & Stay Updated
